#unleash the first in class "Beast", page-23

Anyone keen to share thoughts on what will possibly come from the meeting with HIV Experts? What will the road map look like moving forward?

Im thinking they will possibly need to do another phase 2 trial with a larger sample size to further characterise the effect of Bit225. (There is a PDF on guidline recommendations for HIV drug development on the FDA website, worth a read) sorry link not working when I paste it.

The new drugs that have recently come into the market have warnings not to use them if the patient currently has Hep B.
Maybe they are going to create a first in class to provide for Both Hiv-1 and Hep B patients in the one regimen?

Hopefully not too far off until an update is released.